HPCM
HAE icon

High Pointe Capital Management’s Haemonetics HAE Stock Holding History

High Pointe Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-57,240
Closed -$2.28M – 168
2013
Q3 		$2.28M Hold
57,240
– – 0.92% 43
2013
Q2 		$2.37M Buy
+57,240
New +$2.32M 1.04% 19

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

High Pointe Capital Management's HAE Position: Q4 2013 in Review

High Pointe Capital Management sold out of Haemonetics (HAE) in Q4 2013, closing a stake of 57,240 shares — an estimated $2.28M sold.

High Pointe Capital Management first reported a position in HAE in Q2 2013 and held it in 2 quarters. The position peaked at $2.37M in Q2 2013. 195 funds tracked by Wall St. Rank hold HAE as of Q4 2013.

  • High Pointe Capital Management reported no remaining Haemonetics position as of Q4 2013 after selling out during the quarter.
  • High Pointe Capital Management sold 57,240 Haemonetics shares in Q4 2013, an estimated $2.28M.
  • High Pointe Capital Management first reported a position in Haemonetics in Q2 2013 and held it in 2 quarters.
  • High Pointe Capital Management's Haemonetics position peaked at $2.37M in Q2 2013.
  • 195 funds tracked by Wall St. Rank held Haemonetics as of Q4 2013.

Based on High Pointe Capital Management's 13F filing for Q4 2013, filed 28 Jan 2014.